Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Kotani, Daisuke; Oki, Eiji; Nakamura, Yoshiaki; Yukami, Hiroki; Mishima, Saori; Bando, Hideaki; Shirasu, Hiromichi; Yamazaki, Kentaro; Watanabe, Jun; Kotaka, Masahito; Hirata, Keiji; Akazawa, Naoya; Kataoka, Kozo; Sharma, Shruti; Aushev, Vasily N.; Aleshin, Alexey; Misumi, Toshihiro; Taniguchi, Hiroya; Takemasa, Ichiro; Kato, Takeshi; Mori, Masaki; Yoshino, Takayuki

doi:10.1038/s41591-022-02115-4

articleNature MedicineJan 1, 2023HYBRID OA

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

DKDaisuke Kotani EOEiji Oki YNYoshiaki Nakamura HYHiroki Yukami SMSaori Mishima

National Cancer Center Hospital East · Kyushu University · +12 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II-IV resectable CRC (n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49-24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P

Citation impact

462

total citations

FWCI: 106.06
Percentile: 100%
References: 22

Citations per year

Authors

22

Topics & keywords

Topics

Keywords

Medicine
Internal medicine
Colorectal cancer
Hazard ratio
Oncology
Stage (stratigraphy)
Chemotherapy
Cohort

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.